Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for Chiauranib Capsules for Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

About this update from Shenzhen Chipscreen Biosciences Co. Ltd. Class A

Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for Chiauranib Capsules for Treatment of Metastatic Pancreatic Ductal AdenocarcinomaThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shenzhen Chipscreen Biosciences Co. Ltd. Class A